| |
| |
|
| Insider
Information: |
Goeddel David V |
| Relationship: |
10% Owner |
| City: |
So. San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
21,008,913 |
|
|
Indirect Shares
|
32,725,451 |
|
|
| Direct
Value |
$107,224,205 |
|
|
|
Indirect Value
|
$145,808,454 |
|
|
| Total
Shares |
53,734,364 |
|
|
| Total
Value |
$253,032,660 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
63
|
4
|
|
Stock
price went up :
|
24
|
1
|
| Stock
price went down : |
39
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -0.2%
|
-73.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
3,961,942 |
2014-07-29 |
0 |
Premium* |
|
|
Gritstone Oncology, Inc. |
GRTS |
Managing Partner |
2018-10-02 |
3,102,934 |
2018-10-02 |
0 |
Premium* |
|
|
Ngm Biopharmaceuticals Inc |
NGM |
Director, 10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
|
Rapt Therapeutics, Inc. |
RAPT |
Managing Partner, 10% ... |
2020-09-22 |
5,630,497 |
2019-11-04 |
195,401 |
Premium* |
|
|
Oric Pharmaceuticals, Inc. |
ORIC |
Managing Partner, 10% ... |
2020-04-28 |
4,768,181 |
|
0 |
Premium* |
|
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2020-11-16 |
2,151,026 |
2020-11-16 |
3,799,202 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
|
Tenaya Therapeutics, Inc. |
TNYA |
|
2021-08-03 |
0 |
2024-02-12 |
22,999,565 |
Premium* |
|
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2021-08-25 |
4,309,329 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
145 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 6 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RAPT |
Rapt Therapeutics, Inc. |
Director |
– • • |
2019-11-04 |
4 |
B |
$12.00 |
$7,500,000 |
I/I |
625,000 |
4,982,333 |
2.25 |
- |
|
| IMDZ |
Immune Design Corp. |
10% Owner |
– – • |
2016-09-20 |
4 |
B |
$6.25 |
$5,000,000 |
D/D |
800,000 |
3,961,942 |
2.45 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
General Partner |
– – • |
2021-05-05 |
4 |
A |
$0.00 |
$0 |
I/I |
809,826 |
48,406 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
10% Owner |
– – • |
2020-11-16 |
4 |
S |
$36.40 |
$34,653,637 |
D/D |
(952,023) |
2,151,026 |
0 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2022-06-09 |
4 |
B |
$13.50 |
$13,286,174 |
I/I |
984,161 |
90,442 |
2.25 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
10% Owner |
– – • |
2020-11-16 |
4 |
S |
$36.40 |
$39,134,841 |
I/I |
(1,075,133) |
2,429,180 |
0 |
% |
|
| NRIX |
Nurix Therapeutics, Inc. |
General Partner |
– – • |
2021-05-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,488,027) |
0 |
0 |
- |
|
| TNYA |
Tenaya Therapeutics, Inc. |
Director |
– • • |
2023-02-08 |
4 |
B |
$2.60 |
$3,900,000 |
I/I |
1,500,000 |
11,370,274 |
2.25 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2019-04-08 |
4 |
B |
$16.00 |
$30,000,000 |
I/I |
1,875,000 |
15,634,091 |
2.25 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
General Partner |
– – • |
2021-05-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
1,394,333 |
0 |
- |
|
| TNYA |
Tenaya Therapeutics, Inc. |
|
– • • |
2024-02-12 |
4 |
B |
$4.50 |
$9,999,999 |
I/I |
2,222,222 |
13,599,275 |
0.01 |
- |
|
| IMDZ |
Immune Design Corp. |
10% Owner |
– – • |
2014-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,762,926 |
2,762,926 |
0 |
- |
|
| GRTS |
Gritstone Oncology, Inc. |
Managing Partner |
– – – |
2018-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,102,934 |
3,102,934 |
0 |
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Managing Partner |
– – • |
2020-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,693,181 |
4,768,181 |
0 |
- |
|
| RAPT |
Rapt Therapeutics, Inc. |
Director |
– • • |
2019-11-04 |
4 |
A |
$0.00 |
$0 |
I/I |
6,102,151 |
145,401 |
0 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
Managing Partner |
– • • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,672,548 |
686,274 |
0 |
- |
|
| TNYA |
Tenaya Therapeutics, Inc. |
Director |
– • • |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
9,346,124 |
4,985,570 |
0 |
- |
|
| TNYA |
Tenaya Therapeutics, Inc. |
Director |
– • • |
2022-11-21 |
4 |
B |
$2.60 |
$24,999,998 |
I/I |
9,615,384 |
9,615,384 |
2.25 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
13,283,134 |
13,759,091 |
0 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2024-04-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(21,874,413) |
0 |
0 |
- |
|
145 Records found
|
|
Page 6 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
